Pulmonary arterial hypertension (PAH) is a devastating disease without effective drugs
available for its treatment. An in-depth exploration of the pathogenesis of PAH, as well as inquiry
into potential therapeutic targets, remains an urgent issue. Non-coding RNAs (ncRNAs) have
arisen as key players in malignant tumors, cardiovascular diseases and more recently in PAH
progression and development. Network pharmacology is a new discipline based on system biology,
which can predict potential therapeutic targets in diseases regulated by multiple genes. In this
review, we discuss the current knowledge of ncRNAs and network pharmacology regulated
genes involved in PAH, as well as the search for potential drug targets for PAH.